With the pandemic, numerous institutions have entered a race to produce a vaccine against the disease that has worried the entire population. Last Tuesday (14), the modern biotechnology company, from the United States, announced advances in its vaccine against COVID-19. With this, the company progresses to phase 3 of the schedule, scheduled for the next 27th, when 30 thousand people will participate in the test.
The idea behind Moderna’s vaccine is to use the genetic material from the new coronavirus (RNA) to induce the body to produce antibodies to fight the microorganism that causes COVID-19. In the first two phases of testing the vaccine, 45 people aged 18 to 55 received the immunizer. In this, the researchers behind the development of this vaccine candidate found antibodies capable of neutralizing the virus responsible for this pandemic.
Basically, the test participants received three doses of the immunizer: one lighter, one intermediate, and one last heavier. In the previous phase, the intermediate dose (with 100 micrograms of the immunizer) will be used. The study is expected to last until October 2022, but the company estimates it will have results before that date. The Moderna laboratory has even declared that it already has enough doses for all the research and can produce 500 million of them per year.
The vaccine race
With the pandemic, numerous institutions have entered a race to produce a vaccine against COVID-19 (Image: Pexels)
Researchers worldwide are working on developing an efficient vaccine against the new coronavirus (SARS-CoV-2). Russia’s formula for immunization has completed its clinical tests. If the next steps go as expected, some people should receive the vaccine ready as early as August.
Meanwhile, the government of São Paulo opened last Tuesday (14), the registration for volunteers interested in participating in the CoronaVac vaccine tests, developed by the Chinese laboratory Sinovac Biotech with the participation of the Butantan Institute. It is worth mentioning that this new stage of research for the vaccine is aimed only at health professionals who are in direct contact with cases of COVID-19.
In turn, the Oxford vaccine against COVID-19 may have its registration released only in June 2021. According to WHO (World Health Organization), it has been the most advanced and advanced in the world.
